JP7042744B2 - トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 - Google Patents

トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 Download PDF

Info

Publication number
JP7042744B2
JP7042744B2 JP2018540128A JP2018540128A JP7042744B2 JP 7042744 B2 JP7042744 B2 JP 7042744B2 JP 2018540128 A JP2018540128 A JP 2018540128A JP 2018540128 A JP2018540128 A JP 2018540128A JP 7042744 B2 JP7042744 B2 JP 7042744B2
Authority
JP
Japan
Prior art keywords
cancer
substituted
disease
syndrome
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018540128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509986A (ja
JP2019509986A5 (https=
Inventor
リュー ジュン
ヘ キシンリ
ポンパー マーティン
ミン イル
ユー ビャオ
ワン シャオリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2019509986A publication Critical patent/JP2019509986A/ja
Publication of JP2019509986A5 publication Critical patent/JP2019509986A5/ja
Application granted granted Critical
Publication of JP7042744B2 publication Critical patent/JP7042744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
JP2018540128A 2016-02-04 2017-02-03 トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 Active JP7042744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291416P 2016-02-04 2016-02-04
US62/291,416 2016-02-04
PCT/US2017/016527 WO2017136739A1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2019509986A JP2019509986A (ja) 2019-04-11
JP2019509986A5 JP2019509986A5 (https=) 2020-02-27
JP7042744B2 true JP7042744B2 (ja) 2022-03-28

Family

ID=59500284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540128A Active JP7042744B2 (ja) 2016-02-04 2017-02-03 トリプトライドのグルコース・コンジュゲート、その類縁体及び使用

Country Status (8)

Country Link
US (2) US10695319B2 (https=)
EP (1) EP3411121B1 (https=)
JP (1) JP7042744B2 (https=)
CN (1) CN108601952B (https=)
AU (1) AU2017214572A1 (https=)
CA (1) CA3013619A1 (https=)
MX (1) MX2018009406A (https=)
WO (1) WO2017136739A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN109897053B (zh) * 2019-03-28 2020-05-29 中国医学科学院医药生物技术研究所 雷斯吲哚甲及其制备方法和抗丙型肝炎病毒用途
US11660285B2 (en) 2019-12-30 2023-05-30 Guangdong Provincial Hospital of TCM Triptolide acrylate, preparation method therefor and use thereof
CN111040018A (zh) * 2019-12-30 2020-04-21 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 丙烯酸雷公藤甲素酯、其制备方法及其应用
EP4114468A4 (en) * 2020-03-02 2025-04-09 The Johns Hopkins University GLUCOSETRIPTOLIDE CONJUGATES AND USES THEREOF
CN116583303A (zh) * 2020-08-21 2023-08-11 瑞阳公司 雷公藤甲素缀合物和其用途
CN115286684A (zh) * 2022-05-20 2022-11-04 福建医科大学 一种糖与雷公藤内酯醇或其衍生物的缀合物及其制备方法与应用
KR102821060B1 (ko) 2023-03-09 2025-06-16 미네암리타 테라퓨틱스, 엘엘씨 위암의 치료를 위한 약물 조합

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099051A1 (en) 2001-01-19 2002-07-25 Fidler John M. Anticancer treatment using triptolide prodrugs
US20140107077A1 (en) 2009-05-07 2014-04-17 Regents Of The University Of Minnesota Triptolide prodrugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218367B1 (en) * 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
WO2002074759A1 (en) 2001-03-15 2002-09-26 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099051A1 (en) 2001-01-19 2002-07-25 Fidler John M. Anticancer treatment using triptolide prodrugs
US20140107077A1 (en) 2009-05-07 2014-04-17 Regents Of The University Of Minnesota Triptolide prodrugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAMADA Hiroki et al.，Chemo-enzymatic Synthesis of Propionyl-ester-linked Taxol-monosaccharide Conjugate and its Drug Delivery System Using Hybrid-Bio-nanocapsules Targeting Brain Glioma Cells，CLINICAL MEDICINE INSIGHT:WOMEN'S HEALTH，2013年，vol.6，pp.71-75
LIU Der-Zen et al.，Synthesis of 2'-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，2007年01月19日，vol.17, no.3，pp.617-620
PubChem CID:101239577，2015年12月18日，[検索日 2020.12.15]

Also Published As

Publication number Publication date
JP2019509986A (ja) 2019-04-11
EP3411121A1 (en) 2018-12-12
MX2018009406A (es) 2018-11-09
CN108601952B (zh) 2022-03-04
WO2017136739A1 (en) 2017-08-10
AU2017214572A1 (en) 2018-08-16
US10695319B2 (en) 2020-06-30
EP3411121B1 (en) 2024-09-11
US20200297693A1 (en) 2020-09-24
CN108601952A (zh) 2018-09-28
CA3013619A1 (en) 2017-08-10
US20190038596A1 (en) 2019-02-07
EP3411121A4 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
JP7042744B2 (ja) トリプトライドのグルコース・コンジュゲート、その類縁体及び使用
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2019529444A5 (https=)
JP6557744B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2016506916A5 (https=)
JP2019509986A5 (https=)
ES2978337T3 (es) Combinación de regonafenib y nivolumab para el tratamiento contra el cáncer
JP5976923B2 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
RU2697551C2 (ru) Новые производные peg
WO2007023778A1 (ja) 新規抗癌併用薬
AU2024224138A1 (en) Compositions and methods for targeting tumor-associated macrophages
ES2887426T3 (es) Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
WO2024175042A1 (zh) 药物偶联物治疗肿瘤疾病的用途及方法
HK1240958A1 (en) Peg derivative
HK1240958B (zh) Peg衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220315

R150 Certificate of patent or registration of utility model

Ref document number: 7042744

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250